HeyJaredJames Waldron
- Indexed articles, last 90 days
- 11
- Latest publication
- Oct 1, 2026
- Outlet visibility, for FierceBiotech
- Top 500K sites
- Earliest in this view
- Sep 24, 2026
Latest articles
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26 (opens the original)
Read excerpt
A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector has moved beyond the avalanche of redundancies experienced last year. Fierce reported on 21 announcements from biopharmas about layoffs in their business between July and September. This was only slightly above the 17 announcements for the second quarter and two-thirds of the 33 reports in the first three months of this year. The largest announcement in the most recent quar
GSK continues to stock up on Wave's RNA drugs with liver-focused program (opens the original)
Read excerpt
GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration. Under the partners’ original agreement back in 2022, GSK paid $170 million for the option to advance up to eight programs using Wave’s RNA platform. Of those, GSK had already selected four to take forward by the start of this year, with Wave still working on preparing another three for GSK to take its pick. This morning’s announcement concerns a smal
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal (opens the original)
Read excerpt
Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks—although the study missed a secondary endpoint tied to a breathing test. The San Diego-based biotech evaluated rademikibart as an add-on to standard of care in the mid-stage Seabreeze STAT COPD study of 159 patients who have previously experienced an acute chronic obstructive pulmonary disease (COPD) exacerbation. These patients received either rademiki
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody (opens the original)
Read excerpt
Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. The pharma evaluated two doses of the ILT7-targeting IgG1 monoclonal antibody in a phase 2 study of 72 patients with discoid lupus, an autoimmune condition marked by mostly painless sores on the skin. Amgen disclosed in its earnings results back in February that the trial had hit its primary endpoint by significantly reducing dise
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui (opens the original)
Read excerpt
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China. The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor agonist. In return for the ex-China rights to the drug, Novo is also on the line for potential milestone payments that could eventually bring the deal’s total value up to $2.6 billion. Hengrui has designed the candidate, dubbed HRS-1596, for on
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For FierceBiotech, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.